Posted on 14 January, 2013

“This agreement builds on a successful pilot study to test the suitability of the OcellO platform for screening Merus’ therapeutic bispecific antibodies,” said Dr. Leo Price, Chief Scientific Officer at OcellO. “It aims to establish a long-term relationship between OcellO and Merus.”

Mark Throsby, Chief Operating Officer at Merus, commented: “The strength of our approach is its ability to generate thousands of full-length, bispecific human IgG antibodies addressing combinations of targets expressed by tumor cells. OcellO is able to provide high quality data on the functional properties of large panels of bispecific antibodies. These data can’t be obtained from other in vitro screening assays and are pivotal in identifying antibody leads with unique modes of action.